Investors bet weight-loss drugs will fatten contract manufacturers’ profits first

Shares of Indian contract development and manufacturing companies that are already able to manufacture blockbuster drugs such as semaglutide have jumped 7-141% over the past year, while those of drug formulators have returned -12% to 1%. What explains the stark difference in sentiment?

Markets